CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04+0.00 (0.00%)
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
CytomX Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
CytomX Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $74.55M, up 19.7% year over year. For fiscal 2025 it was $68.73M, down 17.6% from the year before. Over ten years it grew 9.3% a year on average. The highest annual figure on record is $131.62M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.73M | -17.6% |
| FY2024 | Dec 31, 2024 | $83.38M | +7.3% |
| FY2023 | Dec 31, 2023 | $77.68M | -30.4% |
| FY2022 | Dec 31, 2022 | $111.65M | -2.2% |
| FY2021 | Dec 31, 2021 | $114.19M | +1.1% |
| FY2020 | Dec 31, 2020 | $112.94M | -14.2% |
| FY2019 | Dec 31, 2019 | $131.62M | +26.7% |
| FY2018 | Dec 31, 2018 | $103.87M | +12.6% |
| FY2017 | Dec 31, 2017 | $92.28M | +68.5% |
| FY2016 | Dec 31, 2016 | $54.76M | +93.1% |
| FY2015 | Dec 31, 2015 | $28.36M | +0.2% |
| FY2014 | Dec 31, 2014 | $28.30M | +159.9% |
| FY2013 | Dec 31, 2013 | $10.89M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $16.48M | +7.7% |
| Q2 FY2026 | Jun 30, 2026 | $17.60M | +32.1% |
| Q1 FY2026 | Mar 31, 2026 | $19.24M | +2.0% |
| Q4 FY2025 | Dec 31, 2025 | $21.24M | +43.6% |
| Q3 FY2025 | Sep 30, 2025 | $15.30M | -28.4% |
| Q2 FY2025 | Jun 30, 2025 | $13.32M | -47.1% |
| Q1 FY2025 | Mar 31, 2025 | $18.87M | -14.4% |
| Q4 FY2024 | Dec 31, 2024 | $14.79M | -23.7% |
| Q3 FY2024 | Sep 30, 2024 | $21.37M | +29.9% |
| Q2 FY2024 | Jun 30, 2024 | $25.17M | +21.8% |
| Q1 FY2024 | Mar 31, 2024 | $22.05M | +4.1% |
| Q4 FY2023 | Dec 31, 2023 | $19.39M | -0.9% |
| Q3 FY2023 | Sep 30, 2023 | $16.45M | -45.8% |
| Q2 FY2023 | Jun 30, 2023 | $20.67M | -33.7% |
| Q1 FY2023 | Mar 31, 2023 | $21.18M | -30.7% |
| Q4 FY2022 | Dec 31, 2022 | $19.56M | -46.5% |
| Q3 FY2022 | Sep 30, 2022 | $30.37M | +4.2% |
| Q2 FY2022 | Jun 30, 2022 | $31.16M | +19.4% |
| Q1 FY2022 | Mar 31, 2022 | $30.56M | +36.6% |
| Q4 FY2021 | Dec 31, 2021 | $36.58M | +66.2% |
| Q3 FY2021 | Sep 30, 2021 | $29.14M | +21.2% |
| Q2 FY2021 | Jun 30, 2021 | $26.10M | +8.5% |
| Q1 FY2021 | Mar 31, 2021 | $22.37M | -47.7% |
| Q4 FY2020 | Dec 31, 2020 | $22.01M | -39.6% |
| Q3 FY2020 | Sep 30, 2020 | $24.05M | -14.0% |
| Q2 FY2020 | Jun 30, 2020 | $24.07M | -22.0% |
| Q1 FY2020 | Mar 31, 2020 | $42.81M | +17.7% |
| Q4 FY2019 | Dec 31, 2019 | $36.44M | +28.7% |
| Q3 FY2019 | Sep 30, 2019 | $27.97M | +1.5% |
| Q2 FY2019 | Jun 30, 2019 | $30.84M | +20.7% |
| Q1 FY2019 | Mar 31, 2019 | $36.38M | +62.0% |
| Q4 FY2018 | Dec 31, 2018 | $28.31M | +36.7% |
| Q3 FY2018 | Sep 30, 2018 | $27.55M | -4.7% |
| Q2 FY2018 | Jun 30, 2018 | $25.55M | -9.0% |
| Q1 FY2018 | Mar 31, 2018 | $22.46M | +54.1% |
| Q4 FY2017 | Dec 31, 2017 | $20.70M | +34.9% |
| Q3 FY2017 | Sep 30, 2017 | $28.92M | – |
| Q2 FY2017 | Jun 30, 2017 | $28.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.58M | – |
| Q4 FY2016 | Dec 31, 2016 | $15.35M | – |
See a number that looks wrong?